IRF9 and COVID-19: This pattern of expression contrasts with that observed in a patient with IRF9 deficiency and mild COVID-19 with positive PCR results for SARS-CoV-2, who was treated with casirivimab and imdevimab on day 2 after hospital admission (Lévy et al., 2021; Fig. 5 A).